Table 2.

Potential therapeutic agents for targeting the inflammasome in carcinogenesis

Agent	Target	Outcome and acting mechanism	Reference no.
Anakinra	IL-1β receptor	Inhibits the IL-6 production and enhances the progress-free survival of patients with indolent myeloma	90
		Is considered as an attractive therapeutic approach by blocking the IL-1β-mediated IL-6 production in Castleman’s disease	91
		Significantly suppresses the growth of breast cancer and bone metastasis through reducing cell proliferation and angiogenesis	92
Thalidomide	NLRP3	Exerts inhibitory effects on the NLRP3 inflammasome through blocking of the CASP1 activity	82, 83
CRID3	NLRP3, AIM2	Blocks the oligomerization of ASC to inhibit the inflammasome activation	86, 87
MCC950	NLRP3	Is a small molecule inhibitor for the canonical and non-canonical NLRP3 activation to block the oligomerization of ASC	88

CRID3, cytokine release inhibitory drug 3; MCC950, 1-(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)-3-[4-(2-hydroxypropan-2-yl)furan-2-yl]sulfonylurea; IL, interleukin; NLRP, nucleotide-binding domain and leucine-rich repeat containing receptor protein; AIM, absent in melanoma; CASP1, caspase 1; ASC, apoptosis-associated speck-like protein containing a caspase recruitment and activation domain.